BioSpace News Archive

Amryt today announces that its unaudited financial results for the first quarter 2022 will be released on Wednesday, May 4, 2022at 0700 ET/1200 BST.

Plus Therapeutics, Inc. announced that the Company will report first quarter 2022 financial results on Thursday, April, 21, 2022, after market close.

BeyondSpring Inc. today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer’s Disease research, has announced that the last patient has completed treatment in the blinded phase of their late-stage clinical trial, Lucidity.

P3 Health Partners, Inc. today announced that the Company expects to release its financial results for the fourth quarter and full year ended December 31, 2021 on Monday April 25, 2022 after the market closes.

BridGene Biosciences, Inc. today announced that two abstracts have been accepted for poster presentation during the Cambridge Health Institute’s Inaugural Drug Discovery Chemistry Conference.

Purigen Biosystems, Inc., a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples, today announced a new distribution agreement with GC biotech BV.

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has completed its previously announced acquisition of control over BioStrand BV, BioKey BV, and BioClue BV (hereinafter collectively referred to as “BioStrand”).

Inozyme Pharma, Inc. today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) for toripalimab, a PD-1 inhibitor, for the treatment of small cell lung cancer (“SCLC”).